Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 7, 2006, Pages 2847-2856

  De Paiva, Cintia S ^a   Corrales, Rosa M ^a   Villarreal, Arturo L ^a   Farley, William ^a   Li, De Quan ^a   Stern, Michael E ^b   Pflugfelder, Stephen C ^a  

^a CULLEN EYE INSTITUTE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; INVOLUCRIN; METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT; MEMBRANE PROTEIN; MESSENGER RNA; OCCLUDIN; OREGON GREEN BAPTA DEXTRAN; OREGON GREEN BAPTA-DEXTRAN; ORGANIC COMPOUND; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN PRECURSOR; SPRR2A PROTEIN, MOUSE; TRANSGLUTAMINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DESQUAMATION; DRY EYE; IMMUNOFLUORESCENCE TEST; LASER MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CONFOCAL MICROSCOPY; DISEASE MODEL; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; PERMEABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRY EYE SYNDROMES; EPITHELIUM, CORNEAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MEMBRANE PROTEINS; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; ORGANIC CHEMICALS; PERMEABILITY; PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSGLUTAMINASES;

EID: 33746713884     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1281     Document Type: Article

References (40)

1. Hemady R, Chu W, Foster CS. Keratoconjunctivitis sicca and corneal ulcers. Cornea. 1990;9:170-173.
2. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982;89:1173-1180.
3. Musch DC, Sugar A, Meyer RF. Demographic and predisposing factors in corneal ulceration. Arch Ophthalmol. 1983;101:1545-1548.
4. Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca: treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract. 1990;20:583-613.
5. Jehangir S. Dry eye syndrome in a Pakistani community. J Pak Med Assoc. 1990;40:66-67.
6. Nelson JD. Simultaneous evaluation of tear turnover and corneal epithelial permeability by fluorophotometry in normal subjects and patients with keratoconjunctivitis sicca (KCS). Trans Am Ophthalmol Soc. 1995;93:709-753.
7. Feenstra RPG, Tseng SCG. Comparison of fluorescein and rose bengal staining. Ophthalmology. 1992;99:605-617.
8. Yokoi N, Kinoshita S. Clinical evaluation of corneal epithelial barrier function with the slit-lamp fluorophotometer. Cornea. 1995;14:485-489.
9. Gobbels M, Spitznas M. Effects of artificial tears on corneal epithelial permeability in dry eyes. Graefes Arch Clin Exp Ophthalmol. 1991;229:345-349.
10. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology. 1992;99:873-878.
11. Pflugfelder SC, Tseng SCG, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tearfilm disorders known to cause ocular irritation. Cornea. 1998;17:38-56.
12. Rolando M, Iester M, Macri A, Calabria G. Low spatial-contrast sensitivity in dry eyes. Cornea. 1998;17:376-379.
13. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-639.
14. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Am J Ophthalmol. 2004;137:337-342.
15. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-457.
16. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166:61-71.
17. Chen Z, de Paiva CS, Luo L, Kretzer FL, Pflugfelder SC, Li DQ. Characterization of putative stem cell phenotype in human limbal epithelia. Stem Cells. 2004;22:355-366.
18. de Paiva CS, Chen Z, Corrales RM, Pflugfelder SC, Li DQ. ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells. 2005;23:63-73.
19. de Paiva CS, Pflugfelder SC. Corneal epitheliopathy of dry eye induces hyperesthesia to mechanical air jet stimulation. Am J Ophthalmol. 2004;137:109-115.
20. Ubels JL, McCartney MD, Lantz WK, Beaird J, Dayalan A, Edelhauser HF. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol. 1995;113:371-378.
21. Li DQ, Tseng SC. Three patterns of cytokine expression potentially involved in epithelial-fibroblast interactions of human ocular surface. J Cell Physiol. 1995;163:61-79.
22. Corrales RM, Galarreta DJ, Herreras JM, Calonge M, Chaves FJ. [Normal human conjunctival epithelium expresses MUC13, MUC15, MUC16 and MUC17 mucin genes.] Arch Soc Esp Oftalmol. 2003;78:375-381.
23. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293-4301.
24. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Proand anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
25. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512.
26. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703-1709.
27. Wang Y, Zhang J, Yi XJ, Yu FS. Activation of ERK1/2 MAP kinase pathway induces tight junction disruption in human corneal epithelial cells. Exp Eye Res. 2004;78:125-136.
28. Adhikary G, Crish J, Lass J, Eckert RL. Regulation of involucrin expression in normal human corneal epithelial cells: a role for activator protein one. Invest Ophthalmol Vis Sci. 2004;45:1080-1087.
29. Zeigler ME, Chi Y, Schmidt T, Varani J. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol. 1999;180:271-284.
30. Reunanen N, Li SP, Ahonen M, Foschi M, Han J, Kahari VM. Activation of p38a MAPK enhances collagenase-1 (MMP-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem. 2002;277:32360-32368.
31. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein- 1 (AP-1) and nuclear factor kappa B (NF-kappaB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21:251-262.
32. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 2001;29:4361-4372.
33. Woodgett JR, Avruch J, Kyriakis JM. Regulation of nuclear transcription factors by stress signals. Clin Exp Pharmacol Physiol. 1995;22:281-283.
34. Toh ML, Yang Y, Leech M, Santos L, Morand EF. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum. 2004;50:3118-3128.
35. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol. 2002;22:7802-7811.
36. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 2001;20:7108-7116.
37. Suk K. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett. 2004;366:167-171.
38. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45:4302-4311.
39. de Paiva CS, Lindsey JL, Pflugfelder SC. Assessing the severity of keratitis sicca with videokeratoscopic indices. Ophthalmology. 2003;110:1102-1109.
40. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811-816.